

## Author's Accepted Manuscript

Does oral administration of ketamine accelerate response to treatment in major depressive disorder? Results of a double-blind controlled trial

Somaye Arabzadeh, Elham Hakkikazazi, Nazila Shahmansouri, Abbas Tafakhori, Alireza Ghajar, Morteza Jafarinia, Shahin Akhondzadeh



PII: S0165-0327(17)32513-2  
DOI: <https://doi.org/10.1016/j.jad.2018.02.056>  
Reference: JAD9602

To appear in: *Journal of Affective Disorders*

Received date: 5 December 2017  
Revised date: 16 February 2018  
Accepted date: 19 February 2018

Cite this article as: Somaye Arabzadeh, Elham Hakkikazazi, Nazila Shahmansouri, Abbas Tafakhori, Alireza Ghajar, Morteza Jafarinia and Shahin Akhondzadeh, Does oral administration of ketamine accelerate response to treatment in major depressive disorder? Results of a double-blind controlled trial, *Journal of Affective Disorders*, <https://doi.org/10.1016/j.jad.2018.02.056>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting galley proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Does oral administration of ketamine accelerate response to treatment in major depressive disorder? Results of a double-blind controlled trial

Somaye Arabzadeh<sup>a1</sup>, Elham Hakkikazazi<sup>a1</sup>, Nazila Shahmansouri<sup>b1</sup>, Abbas Tafakhori<sup>c</sup>, Alireza Ghajar<sup>a</sup>, Morteza Jafarinia<sup>b</sup>, Shahin Akhondzadeh<sup>a\*</sup>

<sup>a</sup>Psychiatric Research Center, Roozbeh Hospital, Tehran University of Medical sciences, Tehran, Iran

<sup>b</sup>Psychosomatic Research Center, Tehran University of Medical sciences, Tehran, Iran

<sup>c</sup>Iranian Center of Neurological Research, Neuroscience Institute, Tehran University of Medical Science.

\*Corresponding author: Psychiatric Research Center, Roozbeh Hospital, Tehran University of Medical Sciences, South Kargar Street, Tehran 13337, Iran. Tel.: (+9821) 55419113; Fax: (+9821) 55412222. s.akhond@neda.net

Abstract

Background:

Major depressive disorder (MDD) exerts a high health and financial burden on society. The conventional pharmacotherapies for MDD are partially effective and the response to medication often starts with some delay. There are recent reports of antidepressant effects for oral ketamine.

---

<sup>1</sup> The first three authors contributed equally to this work

Download English Version:

<https://daneshyari.com/en/article/8815363>

Download Persian Version:

<https://daneshyari.com/article/8815363>

[Daneshyari.com](https://daneshyari.com)